HEK-Dual™ hTLR2

June 12^th 2019 - CONTENTS UPDATE NOTIFICATION
Please note that, for your convenience, these cells are now provided with QUANTI-Blue™ Solution.

Human TLR2 (NF-κB-SEAP / KI-[IL-8]Lucia) dual-reporter HEK293 cells

HEK-Dual™ hTLR2 (NF/IL8) cells were generated from HEK-Dual™ Null cells by stable transfection of the human TLR2 (hTLR2) and CD14 genes. Due to the knockout of TLR3 and TLR5, these cells enable the study of hTLR2 signaling without interference from other TLRs. They respond to very low concentrations of TLR2 agonists such as the synthetic lipopeptide Pam3CSK4. They do not respond to other TLR agonists or to the cytokine TNF-α (see validation sheet).

HEK-Dual™ hTLR2 (NF/IL8) cells are resistant to hygromycin B, Zeocin™ and blasticidin. They should be maintained in growth medium supplemented with hygromycin B and Zeocin™.

References:

1. Ohta K. et al., 2014. TLR-mediated interleukin-8 production by human submandibular gland epithelial cells. Mol Med Rep. 10(5):2377-82.
2. Roebuck KA. et al., 1999. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res. 19(5):429-38. 

Figures

Detection of the NF-kB response using QUANTI-Blue™. HEK-Dual™ hTLR2 (NF/IL8) and HEK-Blue™ hTLR2 cells were stimulated with various TLR agonists: FSL-1 (TLR2 agonist; 30 pg/ml), Pam3CSK4 (TLR2 agonist; 30 pg/ml), HKLM (TLR2 agonist; 1x10⁷ cells/ml), Poly(I:C) (TLR3 agonist; 3 µg/ml), FLA-ST (flagellin from S. typhimurium, TLR5 agonist; 100 ng/ml), and TNF-α (10 ng/ml). The TLR3, TLR5 and TNFR activities due to the endogenous expression of these receptors in HEK-Blue™ hTLR2 cells are shown in gray. After 24 hour incubation, NF-kB-induced SEAP activity was assessed using QUANTI-Blue™ and reading the optical density (OD) at 655 nm. 

Detection of the IL-8 response using QUANTI-Luc™. HEK-Dual™ hTLR2 (NF/IL8) cells were stimulated with TLR2 agonists: FSL-1 (TLR2 agonist; 30 pg/ml), Pam3CSK4 (TLR2 agonist; 30 pg/ml) and HKLM (1x10⁷ cells/ml). After 24 hour incubation, activation of the IL-8 promoter was determined by measuring the relative light units (RLUs) in a luminometer using QUANTI-Luc™, a Lucia luciferase detection reagent. The activation of the IL-8 promoter is expressed as fold increase relative to untreated cells which was calculated by dividing the RLUs for the treated cells by the RLUs for the untreated cells.

Specifications

Antibiotic resistance: blasticidin, hygromycin, Zeocin™

Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™

Guaranteed mycoplasma-free

These cells are covered by a Limited Use License (See Terms and Conditions).

Contents

• 1 vial containing 3-7 x 10⁶ cells
• 1 ml of Hygromycin B Gold (100 mg/ml)
• 1 ml of Zeocin™ (100mg/ml)
• 1 ml of Normocin™ (50 mg/ml)
• 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
• 1 pouch of QUANTI-Luc™ (Lucia luciferase detection medium)

Shipped on dry ice (Europe, USA & Canada)

Details

EC50 values calculated for the NF-kB response using QUANTI-Blue™. HEK-Dual™ hTLR2 (NF/IL8) and HEK-Blue™ hTLR2 cells were stimulated for 24 hours with various TLR2 agonists: FSL-1, Pam3CSK4 and HKLM.